Yew Bio-Pharm Group, Inc. Accounts Receivable, Credit Loss Expense (Reversal)
Yew Bio-Pharm Group, Inc. reported Accounts Receivable, Credit Loss Expense (Reversal) of $506.56 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ProvisionForDoubtfulAccounts · last filed 2021-11-15
- Yew Bio-Pharm Group, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2021-09-30 was $506.56K.
- Yew Bio-Pharm Group, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2021-06-30 was -$5.67K, a 102.93% decline year-over-year.
- Yew Bio-Pharm Group, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2021-03-31 was -$2.28M, a 68468.47% decline year-over-year.
- Yew Bio-Pharm Group, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2020-12-31 was -$55.08K, a 126.59% decline year-over-year.
- Yew Bio-Pharm Group, Inc. accounts receivable, credit loss expense (reversal) for fiscal 2020 was -$30.66K.
- Yew Bio-Pharm Group, Inc. accounts receivable, credit loss expense (reversal) for fiscal 2019 was -$1.69M, a 121.31% decline from fiscal 2018.
- Yew Bio-Pharm Group, Inc. accounts receivable, credit loss expense (reversal) for fiscal 2018 was $7.92M.
| Period end | Accounts Receivable, Credit Loss Expense (Reversal) 3 month | Accounts Receivable, Credit Loss Expense (Reversal) 6 month | Accounts Receivable, Credit Loss Expense (Reversal) 9 month | Accounts Receivable, Credit Loss Expense (Reversal) 12 month |
|---|---|---|---|---|
| 2021-09-30 | $506.56K 10-Q · filed 2021-11-15 | $500.89K derived: sum of 2 quarters · filed 2021-11-15 | -$1.78M 10-Q · filed 2021-11-15 | -$1.84M derived: sum of 4 quarters · filed 2021-11-15 |
| 2021-06-30 | -$5.67K 10-Q · filed 2021-08-16 | -$2.29M 10-Q · filed 2021-08-16 | -$2.34M derived: sum of 3 quarters · filed 2021-08-16 | -$2.52M derived: sum of 4 quarters · filed 2021-11-15 |
| 2021-03-31 | -$2.28M 10-Q · filed 2021-05-17 | -$2.34M derived: sum of 2 quarters · filed 2021-05-17 | -$2.51M derived: sum of 3 quarters · filed 2021-11-15 | -$2.32M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-12-31 | -$55.08K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | -$227.46K derived: sum of 2 quarters · filed 2021-11-15 | -$34.00K derived: sum of 3 quarters · filed 2021-11-15 | -$30.66K 10-K · filed 2021-03-30 |
| 2020-09-30 | -$172.38K 10-Q · filed 2021-11-15 | $21.09K derived: sum of 2 quarters · filed 2021-11-15 | $24.43K 10-Q · filed 2021-11-15 | $231.55K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $193.47K 10-Q · filed 2021-08-16 | $196.81K 10-Q · filed 2021-08-16 | $403.93K derived: sum of 3 quarters · filed 2021-08-16 | -$1.10M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $3.34K 10-Q · filed 2021-05-17 | $210.47K derived: sum of 2 quarters · filed 2021-05-17 | -$1.29M derived: sum of 3 quarters · filed 2021-05-17 | -$2.00M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $207.13K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | -$1.30M derived: sum of 2 quarters · filed 2021-03-30 | -$2.01M derived: sum of 3 quarters · filed 2021-03-30 | -$1.69M 10-K · filed 2021-03-30 |
| 2019-09-30 | -$1.51M 10-Q · filed 2020-11-13 | -$2.21M derived: sum of 2 quarters · filed 2020-11-13 | -$1.90M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | -$708.58K 10-Q · filed 2020-08-14 | -$390.29K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $318.28K 10-Q · filed 2020-06-29 | |||
| 2018-12-31 | $7.92M 10-K · filed 2020-05-14 |